Time dependent risk of gastrointestinal complications induced by non-steroidal anti-inflammatory drug use: a consensus statement using a meta-analytic approach

被引:149
作者
Richy, F
Bruyere, O
Ethgen, O
Rabenda, V
Bouvenot, G
Audran, M
Herrero-Beaumont, G
Moore, A
Eliakim, R
Haim, M
Reginster, JY
机构
[1] Univ Liege, Dept Publ Hlth Epidemiol & Hlth Econ, Liege, Belgium
[2] WHO, Collaborating Ctr Publ Hlth Aspects Osteoarticula, Liege, Belgium
[3] Hop St Marguerite, Ctr Hosp Reg & Univ Marseille, Dept Internal Med & Therapeut, Marseille, France
[4] CHRU Fac Angers, Dept Rheumatol, Angers, France
[5] Dept Rheumatol, Madrid, Spain
[6] The Churchill, Oxford, England
[7] Rambam Med Ctr, Dept Gastroenterol, Haifa, Israel
[8] Merck & Co Inc, Paris, France
关键词
D O I
10.1136/ard.2003.015925
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objectives: To provide an updated document assessing the global, NSAID-specific, and time dependent risk of gastrointestinal (GI) complications through meta-analyses of high quality studies. Methods: An exhaustive systematic search was performed. Inclusion criteria were: RCT or controlled study, duration of 5 days at least, inactive control, assessment of minor or major NSAID adverse effects, publication range January 1985 to January 2003. The publications retrieved were assessed during a specifically dedicated WHO meeting including leading experts in all related fields. Statistics were performed conservatively. Meta-regression was performed by regressing NSAID adjusted estimates against study duration categories. Results: Among RCT data, indolic derivates provided a significantly higher risk of GI complications related to NSAID use than for non-users: RR = 2.25 (1.00; 5.08) than did other compounds: naproxen: RR = 1.83 (1.25; 2.68); diclofenac: RR = 1.73 (1.21; 2.46); piroxicam: RR = 1.66 (1.14; 2.44); tenoxicam: RR = 1.43 (0.40; 5.14); meloxicam: RR = 1.24 (0.98; 1.56), and ibuprofen: RR = 1.19 (0.93; 1.54). Indometacin users had a maximum relative risk for complication at 14 days. The other compounds presented a better profile, with a maximum risk at 50 days. Significant additional risk factors included age, dose, and underlying disease. The controlled cohort studies provided higher estimates: RR = 2.22 (1.7; 2.9). Publication bias testing was significant, towards a selective publication of deleterious effects of NSAIDs from small sized studies. Conclusion: This meta-analysis characterised the "compound'' and "time'' aspects of the GI toxicity of non-selective NSAIDs. The risk/benefit ratio of such compounds should thus be carefully and individually evaluated at the start of long term treatment.
引用
收藏
页码:759 / 766
页数:8
相关论文
共 80 条
[1]   GASTROINTESTINAL DAMAGE ASSOCIATED WITH THE USE OF NONSTEROIDAL ANTIINFLAMMATORY DRUGS [J].
ALLISON, MC ;
HOWATSON, AG ;
TORRANCE, CJ ;
LEE, FD ;
RUSSELL, RI .
NEW ENGLAND JOURNAL OF MEDICINE, 1992, 327 (11) :749-754
[2]   Double-blind, placebo-controlled study on effect of diclofenac sodium and indomethacin on postprandial gastric motility in man [J].
Bassotti, G ;
Bucaneve, G ;
Furno, P ;
Morelli, A ;
Del Favero, A .
DIGESTIVE DISEASES AND SCIENCES, 1998, 43 (06) :1172-1176
[3]   NONSTEROIDAL ANTIINFLAMMATORY DRUGS AND HOSPITALIZATION FOR GASTROESOPHAGEAL BLEEDING IN THE ELDERLY [J].
BEARD, K ;
WALKER, AM ;
PERERA, DR ;
JICK, H .
ARCHIVES OF INTERNAL MEDICINE, 1987, 147 (09) :1621-1623
[4]  
BEARDON PHG, 1989, Q J MED, V71, P497
[5]   A DOUBLE-BLIND, MULTICENTER, PLACEBO CONTROLLED TRIAL OF LORNOXICAM IN PATIENTS WITH OSTEOARTHRITIS OF THE HIP AND KNEE [J].
BERRY, H ;
BIRD, HA ;
BLACK, C ;
BLAKE, DR ;
FREEMAN, AM ;
GOLDING, DN ;
HAMILTON, EBD ;
JAYSON, MIV ;
KIDD, B ;
KOHN, H ;
MILLION, R ;
OLLIER, S ;
SMITH, I ;
WILLIAMS, BD ;
WOOLF, AD .
ANNALS OF THE RHEUMATIC DISEASES, 1992, 51 (02) :238-242
[7]   THE IMPACT OF RESEARCH QUALITY AND STUDY DESIGN ON EPIDEMIOLOGIC ESTIMATES OF THE EFFECT OF NONSTEROIDAL ANTIINFLAMMATORY DRUGS ON UPPER GASTROINTESTINAL-TRACT DISEASE [J].
BOLLINI, P ;
RODRIGUEZ, LAG ;
GUTTHANN, SP ;
WALKER, AM .
ARCHIVES OF INTERNAL MEDICINE, 1992, 152 (06) :1289-1295
[8]   Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. [J].
Bombardier, C ;
Laine, L ;
Reicin, A ;
Shapiro, D ;
Burgos-Vargas, R ;
Davis, B ;
Day, R ;
Ferraz, MB ;
Hawkey, CJ ;
Hochberg, MC ;
Kvien, TK ;
Schnitzer, TJ ;
Weaver, A .
NEW ENGLAND JOURNAL OF MEDICINE, 2000, 343 (21) :1520-1528
[9]   OXAPROZIN IN THE TREATMENT OF PATIENTS WITH TENDINITIS AND BURSITIS - COMPARISON WITH PHENYLBUTAZONE AND PLACEBO [J].
BONO, RF ;
FINKEL, S ;
GOODMAN, HF ;
HANNA, CB ;
RABINOWITZ, SR ;
SHARON, E .
SEMINARS IN ARTHRITIS AND RHEUMATISM, 1986, 15 (03) :90-94
[10]  
Burssens A, 1995, Acta Orthop Belg, V61, P205